High plasma ACTH (adrenocorticotropic hormone) is not a diagnosis on its own but a biochemical signal that something is driving the adrenal-pituitary feedback loop off balance. The causes range from a tiny benign tumor in the pituitary gland to a failing adrenal gland, a hidden cancer in the lung, or even pregnancy. Sorting out what is behind the elevated number requires careful attention to sample handling, targeted stimulation tests, and sometimes invasive procedures, because the ACTH level alone rarely tells you the full story.
Why ACTH Rises in the First Place
ACTH is made by the pituitary gland and tells the adrenal glands to produce cortisol. Cortisol, in turn, feeds back to the pituitary to keep ACTH in check. When that loop breaks, ACTH climbs. The break can happen in two broad ways: the pituitary (or something mimicking it) pumps out too much ACTH regardless of cortisol levels, or the adrenal glands fail to make enough cortisol, so the pituitary keeps ramping up its signal in an attempt to compensate. Understanding which of these two patterns is at work is the first fork in any diagnostic workup.
Pituitary Adenomas and Cushing’s Disease
The most common reason for ACTH-driven cortisol excess is a small, usually benign pituitary tumor called a corticotroph adenoma. These tumors churn out ACTH on their own, overriding the normal feedback signal from cortisol. The result is Cushing’s disease, a specific subset of Cushing’s syndrome defined by its pituitary origin.1PubMed. Cushing’s disease Patients typically show weight gain concentrated around the trunk and face, thinning skin, easy bruising, high blood sugar, and mood changes.
ACTH levels in Cushing’s disease are elevated but often not dramatically so. In one series, patients with surgically confirmed pituitary adenomas had ACTH values ranging from roughly 120 to 330 pg/mL alongside cortisol levels well above normal.2PubMed. Comparison of ACTH secretion in Cushing’s adenoma and clinically silent corticotroph adenoma by cell immunoblot assay These numbers overlap substantially with other causes, which is exactly why a single ACTH measurement cannot clinch the diagnosis.
Ectopic ACTH Syndrome
Sometimes a tumor outside the pituitary gland starts producing ACTH. This ectopic ACTH syndrome accounts for a meaningful minority of ACTH-dependent Cushing’s cases. The lung is the most common harbor, responsible for over 45% of ectopic sources. Bronchial carcinoid tumors make up the largest share (over a quarter of cases), followed by small-cell lung carcinomas and adenocarcinomas at roughly a fifth.3Arquivos Brasileiros de Endocrinologia & Metabologia. Ectopic ACTH syndrome Other tumors linked to ectopic ACTH include pancreatic carcinoids, thymic carcinoids, medullary thyroid carcinomas, and pheochromocytomas.4PubMed. The ectopic ACTH syndrome
The clinical picture can look different from classic Cushing’s disease. Slow-growing carcinoid tumors may produce a gradual Cushingoid appearance that mimics a pituitary source, while aggressive cancers like small-cell lung carcinoma tend to present with rapid-onset hypokalemia, severe weakness, and very high cortisol levels, sometimes before the typical body-shape changes have time to develop. That clinical variability is one reason biochemical testing matters so much.
Primary Adrenal Insufficiency
High ACTH does not always mean too much cortisol. In primary adrenal insufficiency (Addison’s disease), the adrenal glands themselves are damaged, so they cannot respond to ACTH. The pituitary detects the cortisol shortfall and floods the bloodstream with ACTH trying to coax a response that never comes. Elevated ACTH alongside low cortisol and high renin confirms the diagnosis.5PubMed. Addison’s disease
A hallmark clue is skin darkening: ACTH shares a precursor molecule with melanocyte-stimulating hormone, so excess ACTH leads to hyperpigmentation in sun-exposed areas, palmar creases, and gums. Autoimmune destruction of the adrenal cortex is the most common cause in high-income countries, though infections such as tuberculosis remain important worldwide. The treatment is straightforward hormone replacement with glucocorticoids and, when needed, mineralocorticoids, but the elevated ACTH is what points clinicians toward the adrenal glands as the site of failure.
Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a group of inherited enzyme deficiencies that block the adrenal glands from producing cortisol efficiently. The most common form, making up over 90% of cases, is 21-hydroxylase deficiency.6PubMed. Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: from birth to adulthood Without adequate cortisol, the pituitary ramps up ACTH, which in turn overstimulates the adrenal glands. Because the enzyme block prevents cortisol from being made, the steroid precursors pile up and get shunted into androgen production instead.7PubMed Central. The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency
The downstream effects can be serious. In children, the excess androgens often accelerate bone maturation, leading to premature closure of growth plates and shorter adult height.8The Journal of Clinical Endocrinology & Metabolism. Genetics and Pathophysiology of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency In girls, excess androgens may cause ambiguous genitalia at birth. Treatment centers on replacing the missing cortisol (and sometimes aldosterone) to bring ACTH back down and shut off the androgen overflow.
Glucocorticoid Resistance Syndrome
A rarer cause of persistently high ACTH is glucocorticoid resistance, where the body’s cells cannot respond normally to cortisol. The problem traces to mutations in the glucocorticoid receptor gene (NR3C1).9PubMed. Glucocorticoid Resistance Syndrome: A Systematic Review of the Genotypes, Phenotypes, and Their Relationships Early research on affected families showed that the receptor had both reduced affinity for cortisol and reduced numbers in cells, explaining why the pituitary behaves as though cortisol is absent even when blood levels are high. Patients in those families had elevated ACTH that could not be suppressed by dexamethasone.10JCI Insight. Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease.
Clinically, glucocorticoid resistance can be confusing. Cortisol and ACTH are both elevated, which looks like Cushing’s, yet patients often lack the classic Cushingoid appearance because their tissues do not fully “see” the cortisol. They may instead present with signs of androgen or mineralocorticoid excess, such as acne, menstrual irregularities, or high blood pressure with low potassium, because the extra ACTH drives overproduction of other adrenal steroids. Awareness of this condition prevents unnecessary surgery on a pituitary gland that is actually responding appropriately to a faulty receptor.
Non-Neoplastic Causes and Pseudo-Cushing’s
Not every case of mildly elevated ACTH and cortisol points to a tumor. Several common conditions can activate the stress-hormone axis enough to raise ACTH through hypothalamic pathways rather than through an autonomous tumor. These conditions are sometimes grouped under “pseudo-Cushing’s” or, more precisely, non-neoplastic hypercortisolism. The main culprits include major depression and other psychiatric disorders, alcohol abuse, severe obesity with insulin resistance, polycystic ovary syndrome, and end-stage kidney disease.11PubMed. The difficulties of pseudo-Cushing’s syndrome (or “non-neoplastic hypercortisolism”)
Distinguishing non-neoplastic hypercortisolism from true Cushing’s disease is one of the trickiest problems in endocrinology. The biochemical overlap is significant: both can cause mildly elevated cortisol and ACTH with incomplete suppression on dexamethasone testing. Clinical context is the main differentiator. If the cortisol excess resolves when the underlying condition is treated (sobriety, antidepressant therapy, weight loss), the diagnosis was pseudo-Cushing’s.
Lab Pitfalls That Create Falsely High ACTH
Before chasing down a medical cause, it pays to consider whether the ACTH number itself is trustworthy. ACTH is a fragile molecule, and how the blood sample is handled matters enormously.
A systematic review of stability studies found that ACTH concentrations remain within about 10% of baseline when uncentrifuged blood tubes are stored in a refrigerator for up to eight hours. At room temperature, most studies showed acceptable stability for four to six hours, but by eight to twelve hours at room temperature nearly all studies reported degradation beyond the 10% threshold.12PubMed Central. Is the stability of ACTH in whole blood a genuine concern during the preanalytical phase? A systematic review One study found a meaningful shift (over 12% drop) as early as four hours at room temperature, while another using a different assay platform reported less than 10% change up to twelve hours at ambient temperature.13PubMed Central. Preanalytical stability of adrenocorticotropic hormone depends on both time to centrifugation and temperature14PubMed. Evaluation of plasma ACTH stability using the Roche Elecsys immunoassay The practical takeaway: if a sample cannot reach the lab within a couple of hours at room temperature, keep it cold.
Beyond handling, the assay itself can produce false readings. Modern two-site sandwich immunoassays are far better than older methods, but they are still susceptible to interference from heterophile antibodies, which are rogue antibodies in the patient’s blood that bind the assay reagents and generate a spurious signal.15Journal of the Endocrine Society. Assay-Specific Spurious ACTH Results Lead to Misdiagnosis, Unnecessary Testing, and Surgical Misadventure—A Case Series In one documented case, heterophile antibody interference caused falsely elevated ACTH in a patient being evaluated for Cushing’s syndrome, leading to unnecessary invasive investigation before the interference was identified.16PubMed Central. Heterophile Antibody to Adrenocorticotropin Hormone Interfering with the Investigation of Cushing’s Syndrome When the clinical picture does not match the lab result, running the sample on a different assay platform or testing for heterophile antibodies can prevent a diagnostic wild goose chase.17PubMed Central. Detecting the interferences in adrenocorticotropic hormone measurement – three cases reinforcing the efficiency of the complementary clinical and laboratory audit
Telling Pituitary From Ectopic ACTH Sources
Once high ACTH and high cortisol have been confirmed, the next challenge is figuring out whether the ACTH is coming from the pituitary or from a tumor elsewhere. Several tests are used in combination, because none is perfect on its own.
CRH Stimulation Test
Corticotropin-releasing hormone (CRH) is the natural signal from the hypothalamus that tells the pituitary to release ACTH. Pituitary adenomas usually retain some responsiveness to CRH, while ectopic tumors typically do not. So injecting CRH and watching whether ACTH jumps can help separate the two. A large study of 323 patients with ACTH-dependent Cushing’s syndrome found that using optimal cut-offs (a 40% or greater rise in either ACTH or cortisol), the CRH test correctly identified the source in about 91% of cases, with sensitivity of 91% and specificity of 92%.18The Journal of Clinical Endocrinology & Metabolism. Ovine CRH Stimulation and 8 mg Dexamethasone Suppression Tests in 323 Patients With ACTH-Dependent Cushing’s Syndrome
A shorter version of the test focuses on a single time point. One study proposed looking at ACTH 15 minutes after CRH injection: a rise of 43% or more was a strong predictor of pituitary origin, with a positive likelihood ratio of 14 and specificity of 94%.19European Journal of Endocrinology. ACTH after 15 min distinguishes between Cushing’s disease and ectopic Cushing’s syndrome: a proposal for a short and simple CRH test A CRH test that does not provoke a clear ACTH response should raise suspicion for an ectopic source.
High-Dose Dexamethasone Suppression
This classic test gives a large dose of synthetic glucocorticoid (typically 8 mg of dexamethasone) and checks whether cortisol drops. The logic is that a pituitary adenoma still has some sensitivity to negative feedback and will partially suppress, whereas an ectopic tumor will not. In practice, the test has limited diagnostic value. One study found its sensitivity and specificity for identifying a pituitary source were only about 81% and 67%, respectively, with the range of suppression stretching from 0% to 99% for both diagnoses.20PubMed. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome Because of that poor accuracy, the high-dose dexamethasone suppression test is now used mainly in combination with other tests rather than as a standalone tool.21Journal of the Endocrine Society. PMON98 High-dose dexamethasone suppression test in ACTH-dependent Cushing’s syndrome: Lessons learned on the lack of cortisol suppression
Inferior Petrosal Sinus Sampling
When non-invasive tests are inconclusive, catheter-based sampling of the veins draining the pituitary gland (the inferior petrosal sinuses) can settle the question. Blood is drawn simultaneously from those veins and a peripheral vein, and the ACTH levels are compared before and after CRH stimulation. A ratio of central-to-peripheral ACTH of 3 or higher after CRH strongly suggests a pituitary source. In a multicenter Italian study, this ratio was met in 88% of patients with confirmed Cushing’s disease and in none of the patients with ectopic ACTH, yielding a diagnostic accuracy of 90%.22European Journal of Endocrinology. Inferior petrosal sinus sampling in the differential diagnosis of Cushing’s syndrome The procedure requires an experienced interventional radiologist and carries small risks (mainly venous complications), so it is reserved for cases where the non-invasive workup is ambiguous.
Imaging Considerations
Once the source of ACTH has been localized biochemically, imaging helps pinpoint the lesion for treatment. For pituitary adenomas, MRI of the sella turcica is the first-line study. The problem is that many ACTH-producing adenomas are microadenomas, often just a few millimeters across, and a meaningful fraction are too small for MRI to detect reliably.
Newer molecular imaging approaches are being explored for these difficult cases. Gallium-68 DOTATOC PET/CT, which targets somatostatin receptors on pituitary tumors, has shown a localization success rate of about 77%, comparable to MRI.23PubMed Central. 68Ga-DOTATOC PET/CT in the Localization of Pituitary Tumors in Cushing’s Disease A more experimental tracer, Gallium-68 DOTA-CRH, targets CRH receptors on corticotroph adenomas specifically. In a pilot study of 15 patients, it successfully identified the adenoma in every case, including microadenomas that were MRI-occult.24PubMed. Development of (68)Ga DOTA-CRH for PET/CT Imaging of ACTH-Dependent Cushing’s Disease: Initial Study These PET tracers are not yet widely available, but they represent a promising direction for patients whose MRI is negative despite biochemical certainty of a pituitary source.
For ectopic ACTH, imaging usually involves CT or MRI of the chest and abdomen, since the lung and abdominal organs account for the majority of ectopic tumors. Somatostatin-receptor PET/CT can also help localize carcinoid tumors that may be occult on standard cross-sectional imaging.
Surgical and Medical Management
Treatment depends on the underlying cause. For pituitary Cushing’s disease, transsphenoidal surgery (accessing the pituitary through the nose) has been the mainstay for decades.25PubMed. Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease When the adenoma can be identified and fully removed, remission rates are generally favorable, though recurrence is possible years later. If the tumor cannot be found during surgery or if the disease recurs, repeat surgery, radiation therapy, or medical management may be needed.
Medical therapy for Cushing’s disease is typically second-line, used after failed surgery or as a bridge to other treatments. The available drugs fall into three categories: steroidogenesis inhibitors that block cortisol production at the adrenal level (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane), pituitary-directed drugs that reduce ACTH secretion (pasireotide, cabergoline), and a glucocorticoid receptor blocker (mifepristone).26PubMed Central. Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome Among the steroidogenesis inhibitors, osilodrostat has emerged as an effective FDA-approved option.27PubMed Central. Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
For ectopic ACTH syndrome, the ideal treatment is removal of the source tumor. When that is not possible (because the tumor is metastatic or cannot be located), the same cortisol-lowering medications used in pituitary Cushing’s can help control the hypercortisolism. In refractory cases, bilateral removal of the adrenal glands (adrenalectomy) eliminates cortisol production entirely, though it commits the patient to lifelong steroid replacement.
For primary adrenal insufficiency and CAH, the treatment target is different: the goal is to replace the missing cortisol, which in turn brings ACTH down. Adequate glucocorticoid replacement quiets the pituitary’s relentless drive to produce ACTH. In CAH, getting this balance right is a lifelong challenge; too little replacement leaves ACTH and androgens elevated, while too much causes Cushingoid side effects.
Nelson’s Syndrome After Adrenalectomy
A specific complication worth knowing about arises when patients with Cushing’s disease undergo bilateral adrenalectomy without addressing the pituitary tumor. Once both adrenal glands are removed, the cortisol brake on ACTH vanishes completely, and the pituitary adenoma can grow aggressively. This is Nelson’s syndrome, characterized by very high ACTH levels, progressive skin darkening, and an enlarging pituitary mass that may compress surrounding structures. In one series, 11 patients who had not received prophylactic pituitary radiation developed Nelson’s syndrome over a mean follow-up of about four and a half years.28PubMed. Nelson’s syndrome after bilateral adrenalectomy for Cushing’s disease Prophylactic radiation to the pituitary after adrenalectomy can reduce this risk, but the possibility of Nelson’s syndrome is one reason bilateral adrenalectomy is generally reserved as a last resort in Cushing’s disease.
Pregnancy and High ACTH
Pregnancy is an underappreciated physiological cause of elevated ACTH and cortisol. The placenta produces its own CRH (the hypothalamic hormone that stimulates ACTH release), and circulating cortisol and ACTH levels climb steadily throughout gestation, sometimes reaching values that overlap with the range seen in Cushing’s syndrome.29Endocrine Reviews. The Hypothalamic-Pituitary-Adrenal Axis in Pregnancy: Challenges in Disease Detection and Treatment This makes diagnosing true Cushing’s during pregnancy genuinely difficult, because the usual biochemical benchmarks shift. Clinical judgment is critical: worsening hypertension, glucose intolerance beyond what is expected for pregnancy, proximal muscle weakness, and purple striae may point toward pathological excess rather than the normal physiological rise.30PubMed Central. Pregnancy and pituitary disorders: Challenges in diagnosis and management
Testing strategies in pregnant patients are limited. The dexamethasone suppression test loses reliability because the normal pregnancy rise in cortisol-binding globulin and placental CRH can blunt suppression. Urinary free cortisol rises physiologically. In practice, clinicians rely heavily on clinical features, repeated cortisol measurements with attention to circadian rhythm (which is usually preserved in pregnancy but lost in Cushing’s), and MRI when a pituitary source is suspected. Most cases of true Cushing’s discovered during pregnancy are managed medically until delivery, at which point definitive surgical treatment can be pursued.
When ACTH Does Not Fit the Clinical Picture
A recurring theme throughout the diagnostic workup is that ACTH values frequently refuse to cooperate with clean diagnostic categories. Mildly elevated ACTH with borderline cortisol can represent early Cushing’s, pseudo-Cushing’s from depression or alcohol use, a degraded sample, or an assay artifact. Conversely, an ACTH level that seems “appropriately” suppressed may actually be falsely low if the sample sat at room temperature too long before processing.
Clinicians dealing with ambiguous results have several practical options. Repeating the ACTH measurement under controlled conditions (morning draw, chilled tube, prompt transport) eliminates handling-related error. Running the sample on a second assay platform can expose heterophile antibody interference. And stepping back to reassess the clinical picture often matters more than the precise number: a patient with obvious Cushingoid features and an ACTH of 15 pg/mL probably has adrenal Cushing’s syndrome, not a pituitary tumor, regardless of whether 15 is “in range” or slightly above the lower threshold for ACTH-dependent disease. In endocrinology, the numbers inform but do not replace clinical reasoning, and that is especially true for a hormone as labile and context-dependent as ACTH.